Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Denali Therapeutics's Days Payable or its related term are showing as below:
STU:4DN'
s Days Payable Range Over the Past 10 Years
Min: 0 Med: 0 Max: 57384.28
Current: 57384.28
During the past 11 years, Denali Therapeutics's highest Days Payable was 57384.28. The lowest was 0.00. And the median was 0.00.
STU:4DN's Days Payable is ranked better than 98.01% of 703
companies
in the Biotechnology industry
Industry Median: 110.14
vs STU:4DN: 57384.28
Denali Therapeutics's Days Payable
increased
from Jun. 2025 (0.00) to Jun. 2026 (25,765.01).
It may suggest that Denali Therapeuticsdelayed paying its suppliers.
The historical data trend for Denali Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4DN vs RCUS, ALMS, ELVN: Days Payable Comparison
For the Biotechnology subindustry, Denali Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Denali Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (STU:4DN) has a Days Payable of 25,765.01 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Denali Therapeutics and its competitors. According to the industry distribution chart, Denali Therapeutics ranks #14 out of 703 companies in the Biotechnology industry, placing it in the top 2%.
Is Denali Therapeutics' Days Payable too high?
Denali Therapeutics' current Days Payable is 25,765.01. The Biotechnology industry median Days Payable is 110.14. Denali Therapeutics' value of 25,765.01 is 23293% above this industry median. Based on the distribution chart, Denali Therapeutics ranks #14 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Denali Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Days Payable compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #14 out of 703 companies for Days Payable. This places Denali Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median Days Payable is 110.14. Denali Therapeutics' value of 25,765.01 is 23293% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.14, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Denali Therapeutics's current Days Payable of 25,765.01 is 23293% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Denali Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 110.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denali Therapeutics's current Days Payable is 25,765.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Denali Therapeutics (STU:4DN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €21.91 — trading 8326.9% above its estimated fair value. The current Days Payable is 25,765.01 and 23293% above the Biotechnology industry median of 110.14. Denali Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Denali Therapeutics (STU:4DN), the current Days Payable is 25,765.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Denali Therapeutics (STU:4DN) Overvalued in 2026?
Based on GuruFocus' analysis, Denali Therapeutics stock appears to be overvalued.
The current stock price of €21.91 is trading 8326.9% above its estimated GF Value™ of €0.26.
GuruFocus considers Denali Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:4DN:
Days Payable: 25,765.01
GF Value™: €0.26 vs. price of €21.91 (8326.9% above fair value)
Industry Position: 23293% above the Biotechnology median (#14 of 703)
No single metric tells the full story. See the STU:4DN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
39GF Score
Get the complete analysis for STU:4DN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4DN has been successfully added to your 
